Company news

Spyre Therapeutics, Inc. news in 2024

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

December 17, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

December 1, 2024

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 24, 2024

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

November 17, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

November 17, 2024

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potenti...

November 11, 2024

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

November 10, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

October 13, 2024

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

September 30, 2024

Spyre Therapeutics to Participate in Upcoming Investor Conference

September 9, 2024

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 6, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

June 17, 2024

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2024

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

May 14, 2024

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Spyre Therapeutics Announces $180 Million Private Placement

March 17, 2024

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

February 25, 2024

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

February 7, 2024

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

February 4, 2024

Decks in 2024